0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of Archives of Internal Medicine |

In This Issue of Archives of Internal Medicine FREE

Arch Intern Med. 2006;166(7):711. doi:10.1001/archinte.166.7.711.
Text Size: A A A
Published online

RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH COMMON THROMBOPHILIA

Factor V Leiden (FVL) and prothrombin G20210A are independent predictors for a first-ever episode of venous thromboembolism, but it is uncertain whether they also predict recurrence. This meta-analysis of 13 studies involving more than 3000 patients with first-ever venous thromboembolism demonstrates that heterozygous factor V Leiden and prothrombin G20210A are associated with a 1.4-fold and a 1.7-fold increase, respectively, in the odds of recurrent venous thromboembolism. These increases in risk are lower than the risk for a first event and by themselves are unlikely to merit extended-duration anticoagulation in affected persons.

See Article

GEMFIBROZIL IN THE TREATMENT OF DYSLIPIDEMIA

The Helsinki Heart Study was a double-blind, placebo-controlled primary prevention trial among dyslipidemic middle-aged men to test the efficacy of gemfibrozil in the prevention of coronary heart disease. After the 5-year trial, all participants were offered free gemfibrozil treatment, and two thirds of participants in both groups chose the treatment. This 18-year follow-up showed significantly lower coronary heart disease mortality in the group that had started gemfibrozil treatment 5 years earlier than the other group, and the benefit was greatest among those with high body mass index, high triglyceride level, or low high-density lipoprotein cholesterol level.

See Article

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH CORONARY ARTERY DISEASE AND ABSENCE OF HEART FAILURE OR LEFT VENTRICULAR SYSTOLIC DYSFUNCTION

Angiotensin-converting enzyme (ACE) inhibitors have an undisputed efficacy in patients with coronary artery disease and left ventricular dysfunction. This meta-analysis, analyzing 7 trials with long-term (at least 2 years) ACE inhibitor therapy vs placebo in such patients, documents the efficacy of these medications in terms of secondary prevention, with significant reductions in all-cause mortality, cardiovascular mortality, nonfatal myocardial infarction, stroke, resuscitated cardiac arrest, congestive heart failure, myocardial revascularization, and new-onset diabetes in patients without previously known diabetes.

See Article

VENOUS THROMBOSIS AND CONJUGATED EQUINE ESTROGEN IN WOMEN WITHOUT A UTERUS

Postmenopausal hormone therapy has been associated with an increased risk of venous thromboembolism (VT), including deep vein thrombosis and pulmonary embolism, in observational studies and secondary prevention clinical trials. The Women's Health Initiative (WHI) estrogen trial enrolled 10 739 women without a uterus aged 50 to 79 years. Participants were randomized to receive conjugated equine estrogen (0.625 mg/d) or placebo. Over an average of 7.1 years, VT occurred in 111 women randomized to estrogen and in 86 women randomized to placebo (hazard ratio [HR], 1.32). Deep VT was reported in 85 women randomized to estrogen and in 59 women randomized to placebo (HR, 1.47). There were no significant interactions between estrogen use and age, body mass index, or most other VT risk factors. Compared with WHI VT findings for estrogen and previous WHI findings for estrogen plus progestin, the HR for estrogen plus progestin was significantly higher than that for estrogen alone (P = .03), even after adjusting for VT risk factors. An early increased VT risk was associated with use of estrogen, especially within the first 2 years, but this risk elevation was less than that for estrogen plus progestin.

See Article

HYPONATREMIA AND LONG-TERM MORTALITY IN SURVIVORS OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION

This study tested the hypothesis that hyponatremia, a simple marker of neurohormonal activation during the acute phase of infarction, may predict the long-term development of heart failure and death. The study included 978 patients with acute myocardial infarction who survived the index event and were followed up for a median of 31 months after hospital discharge. Hyponatremia (serum sodium level <136 mEq/L) was present during the hospital course in 108 patients (11.0%). In a multivariable Cox model, hyponatremia was an independent predictor of postdischarge death (hazard ratio, 2.0) and readmission for heart failure (hazard ratio, 1.6).

Place holder to copy figure label and caption

Kaplan-Meier plot showing the crude cumulative incidence of admission for the treatment of heart failure (HF) according to sodium level.

Graphic Jump Location

See Article

Figures

Place holder to copy figure label and caption

Kaplan-Meier plot showing the crude cumulative incidence of admission for the treatment of heart failure (HF) according to sodium level.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.